Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD3CAR: B7-H3-CAR T Cells and Radiation for Pediatric Sarcomas
NCT07222735Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jan 2026
- Primary completion
- Nov 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of b7-h3-car t cells in sarcoma, sponsored by St. Jude Children's Research Hospital. Primary endpoints: Dose Limiting Toxicity Rate at 4 weeks and Incidence of Adverse Events at 4 weeks. Started Jan 2026; status: recruiting.
02
Drugs
b7-h3-car t cells
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT07222735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222735.